UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): June 20, 2017

 

Ekso Bionics Holdings, Inc.

(Exact Name of Registrant as specified in its charter)

 

Nevada 001-37854 99-0367049

(State or Other Jurisdiction of

Incorporation)

 (Commission File Number)

(IRS Employer

Identification No.)

 

1414 Harbour Way South, Suite 1201

Richmond, California 94804

(Address of principal executive offices, including zip code)

 

(510) 984-1761

(Registrant’s telephone number, including area code)

 

Not Applicable

(Registrant’s name or former address, if change since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

  

Item 5.07Submission of Matter to a Vote of Security Holders

 

The following provides a summary of votes cast for the proposals on which the stockholders of Ekso Bionics Holdings, Inc. (the “Company”) voted at the annual meeting of stockholders held on June 20, 2017 (the “Annual Meeting”):

 

Proposal 1. The election of eight directors to serve until the next annual meeting of stockholders and the election of their successors.

 

Director Nominee   For   Withheld   Broker Non-Votes
Steven Sherman   5,648,818   1,032,759   10,376,874
Thomas Looby   6,347,375   334,202   10,376,874
Daniel Boren   6,361,036   320,541   10,376,874
Marilyn Hamilton   5,858,101   823,476   10,376,874
Howard Palefsky   6,355,865   325,712   10,376,874
Jack Peurach   6,153,656   527,921   10,376,874
Stanley Stern   5,841,139   840,438   10,376,874
Amy Wendell   6,176,786   504,791   10,376,874

 

Proposal 2. Approval of the Ekso Bionics Holdings, Inc. 2017 Employee Stock Purchase Plan.

 

For   Against   Abstain   Broker Non-Votes
6,104,867   419,302   157,408   10,376,874

 

Proposal 3. Approval of an amendment to the Amended and Restated 2014 Equity Incentive Plan to increase the maximum number of shares available for grant from 3,714,285 shares to 4,714,285 shares.

 

For   Against   Abstain   Broker Non-Votes
5,015,192   1,593,942   72,443   10,376,874

 

Proposal 4. The ratification of the appointment of OUM & Co., LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.

 

For   Against   Abstain   Broker Non-Votes
16,419,641   389,483   249,327   0

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  EKSO BIONICS HOLDINGS, INC.  
     
     
  By: /s/ Maximilian Scheder-Bieschin  
  Name: Maximilian Scheder-Bieschin  
  Title: Chief Financial Officer  
Dated: June 23, 2017